Loomis, Sayles & Company
PTCT icon

Loomis, Sayles & Company’s PTC Therapeutics PTCT Stock Holding History

Loomis, Sayles & Company’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$33.6M Buy
+493,603
New +$35M 0.05% 147
2023
Q3 		– Sell
-1,061,398
Closed -$43.2M – 1002
2023
Q2 		$43.2M Sell
1,061,398
-169,684
-14% -$8.3M 0.07% 129
2023
Q1 		$59.6M Buy
1,231,082
+4,817
+0.4% +$220K 0.1% 99
2022
Q4 		$46.8M Sell
1,226,265
-392,629
-24% -$16.3M 0.09% 119
2022
Q3 		$81.3M Sell
1,618,894
-17,941
-1% -$879K 0.16% 74
2022
Q2 		$65.6M Sell
1,636,835
-9,949
-0.6% -$349K 0.12% 82
2022
Q1 		$61.4M Buy
1,646,784
+110,561
+7% +$4.26M 0.08% 103
2021
Q4 		$61.2M Buy
1,536,223
+247,968
+19% +$9.49M 0.07% 119
2021
Q3 		$47.9M Buy
1,288,255
+383,338
+42% +$15.7M 0.06% 156
2021
Q2 		$38.3M Buy
904,917
+1,951
+0.2% +$83.6K 0.05% 213
2021
Q1 		$42.8M Buy
902,966
+37,506
+4% +$2.23M 0.06% 175
2020
Q4 		$52.8M Buy
865,460
+67,643
+8% +$3.99M 0.07% 126
2020
Q3 		$37.3M Buy
797,817
+131,287
+20% +$6.46M 0.05% 138
2020
Q2 		$33.8M Buy
666,530
+227,379
+52% +$11.2M 0.05% 141
2020
Q1 		$19.6M Buy
439,151
+2,666
+0.6% +$134K 0.04% 168
2019
Q4 		$21M Buy
436,485
+49,258
+13% +$2.09M 0.04% 204
2019
Q3 		$13.1M Buy
+387,227
New +$16.9M 0.03% 289
2015
Q1 		– Sell
-263,918
Closed -$13.7M – 763
2014
Q4 		$13.7M Buy
263,918
+31,312
+13% +$1.38M 0.04% 453
2014
Q3 		$10.2M Buy
+232,606
New +$7.28M 0.03% 483
2014
Q2 		– Sell
-473,215
Closed -$12.4M – 774
2014
Q1 		$12.4M Buy
+473,215
New +$12.7M 0.04% 462

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Loomis, Sayles & Company's PTCT Position: Q1 2026 in Review

Loomis, Sayles & Company opened a new position in PTC Therapeutics (PTCT) in Q1 2026: 493,603 shares worth $33.6M. The stake represents 0.05% of the portfolio and ranks #147 among its holdings. This is a return to the name: Loomis, Sayles & Company previously reported a position in PTCT as recently as Q2 2023.

Loomis, Sayles & Company first reported a position in PTCT in Q1 2014 and has held it in 20 quarters since. The position peaked at $81.3M in Q3 2022. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Loomis, Sayles & Company held 493,603 shares of PTC Therapeutics worth $33.6M as of Q1 2026.
  • PTC Therapeutics was a new Loomis, Sayles & Company position in Q1 2026.
  • PTC Therapeutics made up 0.05% of Loomis, Sayles & Company's portfolio in Q1 2026, its #147 holding.
  • Loomis, Sayles & Company first reported a position in PTC Therapeutics in Q1 2014 and has held it in 20 quarters since.
  • Loomis, Sayles & Company's PTC Therapeutics position peaked at $81.3M in Q3 2022.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Loomis, Sayles & Company's 13F filing for Q1 2026, filed 14 May 2026.